TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals Incorporated (VRTX) is attracting investor attention: Here is what you should know
Vertex Pharmaceuticals (VRTX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...
In the past week, Wolfe Research upgraded Vertex Pharmaceuticals from “Peer Perform” to “Outperform,” citing growing ...
Vertex Pharmaceuticals is anchored by cystic fibrosis as launches lag, JOURNAVX and CASGEVY add little revenue, and growth is ...
Vertex Pharmaceuticals' top line has grown significantly over the years thanks to the approval of Trikafta in 2019. The company recently obtained approval for a gene therapy treatment, Casgevy. Strong ...
Third, this stock provides stability to investors' portfolios in the event the economy takes a turn for the worse in the new ...
Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” ...
Vertex Pharmaceuticals Incorporated VRTX stock has risen 34.4% this year so far against the industry’s decline of 27.6%. The company currently sports a Zacks Rank #1 (Strong Buy) Image Source: Zacks ...
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Growth Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here. During ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback